Pharma Focus Asia

Samsung Biologics and Kurma Partners Establish Strategic Collaboration for Biologics Development and Manufacturing for Kurma's Portfolio Companies

Monday, October 23, 2023

Samsung Biologics, a global Contract Development and Manufacturing Organization (CDMO), has entered into a strategic partnership with Kurma Partners, a European venture capital firm specializing in healthcare and biotechnology. This partnership aims to facilitate the development and manufacturing of biologics for companies within Kurma Partners' portfolio.

Under the terms of the multi-year agreement, Samsung Biologics will provide customized Chemistry, Manufacturing, and Control (CMC) development services. These services will streamline the process from gene to Investigational New Drug (IND), reducing uncertainties in CMC and expediting the selection of lead candidates for entry into first-in-human studies. Portfolio companies associated with Kurma Partners will gain access to Samsung Biologics' cutting-edge facilities, proprietary technology platforms, and their extensive CMC expertise.

Samsung Biologics, expressed his excitement for the partnership, stating, "As we aim to expand our global business presence, we are delighted to collaborate with Kurma Partners to support the growth of pioneering biotech companies. Leveraging our deep expertise in effective scale-up strategies and a diverse portfolio of proprietary platform technologies, we are eager to provide robust CMC solutions that reduce uncertainties, ensure regulatory compliance, and ultimately enhance manufacturing efficiency for our clients."

Kurma Partners, also conveyed his enthusiasm: "We are very excited to partner with Samsung Biologics, a world-leading CDMO with capabilities of the highest industry standards. This partnership will greatly benefit our portfolio of Kurma Biofunds and Kurma Growth Opportunities Fund in advancing large molecule biologics from discovery to the market."

This collaboration underscores Samsung Biologics' ongoing commitment to supporting emerging biotech companies throughout their drug development and manufacturing journey while expanding its presence in key sectors, with a particular focus on the U.S. and European markets.

 

Source: prnewswire.com

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference